Perioperative Management of DIEP Flaps
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03118024 |
Recruitment Status : Unknown
Verified April 2017 by Dr. Alexandra Anker, University of Regensburg.
Recruitment status was: Recruiting
First Posted : April 18, 2017
Last Update Posted : April 18, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mammaplasty Microsurgery Free Tissue Flaps | Drug: Crystalloid Solutions Drug: Catecholamines | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Perioperative Management of Deep Inferior Epgastric Perforator (DIEP) Flap for Breast Reconstruction |
Actual Study Start Date : | March 13, 2017 |
Estimated Primary Completion Date : | March 2019 |
Estimated Study Completion Date : | March 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Fluid restriction
Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
|
Drug: Crystalloid Solutions
crystalloid restrictive anesthesia protocol |
Active Comparator: Catecholamine restriction
Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
|
Drug: Catecholamines
catecholamine restrictive anesthesia protocol
Other Name: Norephinephrine |
- Free flap survival rate [ Time Frame: 5 days postoperatively ]Rates of (partial) flap loss in each study arm
- Period of hospitalization [ Time Frame: up to 14 days ]Length of postoperative hospitalization in each study arm

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
- Informed consent for study participation
- Every patient undergoing breast reconstruction (primary and secondary reconstruction) with deep inferior epigastric perforator flap at our hospital is offered to participate in the study
Exclusion criteria:
- No informed consent for study participation
- Patients with a high thromboembolic risk profile
- During pregnancy and breastfeeding
- Minors
- Patients with a health care proxy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118024
Contact: Alexandra Anker, MD | 0049 941 782 3110 | aanker@caritasstjosef.de |
Germany | |
University hospital of Regensburg | Recruiting |
Regensburg, Germany, 93053 | |
Contact: Anker Alexandra, MD 0049 941 782 3110 aanker@caritasstjosef.de |
Responsible Party: | Dr. Alexandra Anker, Principal Investigator, University of Regensburg |
ClinicalTrials.gov Identifier: | NCT03118024 |
Other Study ID Numbers: |
16-101-0293 |
First Posted: | April 18, 2017 Key Record Dates |
Last Update Posted: | April 18, 2017 |
Last Verified: | April 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
deep inferior epigastric perforator flap fluid restriction catecholamine restriction |